Clairvoyant is a clinical stage biotechnology company that is headquartered in Canada – our purpose is to provide evidence-based psychedelic therapy to Alcohol Use Disorder (AUD) patients, in order to help them live healthier and more enriched lives, and to build stronger communities. The company’s team, with a proven clinical track record and deep drug development experience, has made Clairvoyant the most advanced company developing psilocybin therapy for the treatment of AUD and currently the 2nd most advanced psilocybin drug development company globally. The company was founded with the mission of changing the face of psychedelic therapy with a speed-to-market clinical strategy designed to enable psilocybin therapy in the EU, UK & Canada to treat patients living with AUD beginning in 2026. Clairvoyant is operating a placebo-controlled, randomized, double-blind Phase 2B clinical study, initiating at 15 sites in Canada and the EU.